
HOWL Valuation
Werewolf Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
HOWL Relative Valuation
HOWL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HOWL is overvalued; if below, it's undervalued.
Historical Valuation
Werewolf Therapeutics Inc (HOWL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -3.20. The fair price of Werewolf Therapeutics Inc (HOWL) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.34 USD , Werewolf Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price:1.34
Fair
Undervalued
-0.79
PE
1Y
3Y
5Y
Trailing
Forward
-0.25
EV/EBITDA
Werewolf Therapeutics Inc. (HOWL) has a current EV/EBITDA of -0.25. The 5-year average EV/EBITDA is -0.94. The thresholds are as follows: Strongly Undervalued below -5.95, Undervalued between -5.95 and -3.45, Fairly Valued between 1.57 and -3.45, Overvalued between 1.57 and 4.07, and Strongly Overvalued above 4.07. The current Forward EV/EBITDA of -0.25 falls within the Historic Trend Line -Fairly Valued range.
-0.24
EV/EBIT
Werewolf Therapeutics Inc. (HOWL) has a current EV/EBIT of -0.24. The 5-year average EV/EBIT is -1.55. The thresholds are as follows: Strongly Undervalued below -9.02, Undervalued between -9.02 and -5.28, Fairly Valued between 2.18 and -5.28, Overvalued between 2.18 and 5.92, and Strongly Overvalued above 5.92. The current Forward EV/EBIT of -0.24 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Werewolf Therapeutics Inc. (HOWL) has a current PS of 0.00. The 5-year average PS is 23.21. The thresholds are as follows: Strongly Undervalued below -29.06, Undervalued between -29.06 and -2.93, Fairly Valued between 49.34 and -2.93, Overvalued between 49.34 and 75.48, and Strongly Overvalued above 75.48. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.79
P/OCF
Werewolf Therapeutics Inc. (HOWL) has a current P/OCF of -0.79. The 5-year average P/OCF is -2.22. The thresholds are as follows: Strongly Undervalued below -8.06, Undervalued between -8.06 and -5.14, Fairly Valued between 0.70 and -5.14, Overvalued between 0.70 and 3.62, and Strongly Overvalued above 3.62. The current Forward P/OCF of -0.79 falls within the Historic Trend Line -Fairly Valued range.
-1.02
P/FCF
Werewolf Therapeutics Inc. (HOWL) has a current P/FCF of -1.02. The 5-year average P/FCF is -2.99. The thresholds are as follows: Strongly Undervalued below -7.72, Undervalued between -7.72 and -5.35, Fairly Valued between -0.62 and -5.35, Overvalued between -0.62 and 1.74, and Strongly Overvalued above 1.74. The current Forward P/FCF of -1.02 falls within the Historic Trend Line -Fairly Valued range.
Werewolf Therapeutics Inc (HOWL) has a current Price-to-Book (P/B) ratio of 1.45. Compared to its 3-year average P/B ratio of 1.01 , the current P/B ratio is approximately 43.40% higher. Relative to its 5-year average P/B ratio of 1.16, the current P/B ratio is about 25.18% higher. Werewolf Therapeutics Inc (HOWL) has a Forward Free Cash Flow (FCF) yield of approximately -102.90%. Compared to its 3-year average FCF yield of -55.20%, the current FCF yield is approximately 86.42% lower. Relative to its 5-year average FCF yield of -44.11% , the current FCF yield is about 133.29% lower.
1.45
P/B
Median3y
1.01
Median5y
1.16
-102.90
FCF Yield
Median3y
-55.20
Median5y
-44.11
Competitors Valuation Multiple
The average P/S ratio for HOWL's competitors is 10.68, providing a benchmark for relative valuation. Werewolf Therapeutics Inc Corp (HOWL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HOWL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HOWL in the past 1 year is driven by Unknown.
People Also Watch

SELF
Global Self Storage Inc
5.062
USD
+1.04%

GANX
Gain Therapeutics Inc
1.835
USD
+6.07%

FKWL
Franklin Wireless Corp
4.000
USD
0.00%

VNRX
VolitionRX Ltd
0.720
USD
+3.60%

TYGO
Tigo Energy Inc
1.280
USD
+2.40%

BAYA
Bayview Acquisition Corp
11.120
USD
0.00%

UCL
Ucloudlink Group Inc
3.910
USD
0.00%

SELX
Semilux International Ltd
1.010
USD
0.00%

PRLD
Prelude Therapeutics Inc
0.870
USD
0.00%

CNTB
Connect Biopharma Holdings Ltd
2.050
USD
0.00%
FAQ

Is Werewolf Therapeutics Inc (HOWL) currently overvalued or undervalued?
Werewolf Therapeutics Inc (HOWL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -3.20. The fair price of Werewolf Therapeutics Inc (HOWL) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.34 USD , Werewolf Therapeutics Inc is Undervalued By Fair .

What is Werewolf Therapeutics Inc (HOWL) fair value?

How does HOWL's valuation metrics compare to the industry average?

What is the current P/B ratio for Werewolf Therapeutics Inc (HOWL) as of Aug 18 2025?

What is the current FCF Yield for Werewolf Therapeutics Inc (HOWL) as of Aug 18 2025?

What is the current Forward P/E ratio for Werewolf Therapeutics Inc (HOWL) as of Aug 18 2025?
